Article

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma

2021-07-04

Abstract excerpt

Cancer immunotherapy with checkpoint blockade (CPB) leads to improved outcomes in melanoma and other tumor types, but a majority of patients do not respond. High tumor mutation burden (TMB) and high levels of tumor-infiltrating T cells have been associated with response to immunotherapy, but integrative models to predict clinical benefit using DNA or RNA alone have not been comprehensively explored. We sequenced D...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: abaefb7d-3a0e-50f4-af39-e4a95da142d6
DOI: 10.1101/2021.07.03.450733

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaDOI 10.1101/2021.07.03.450733Read

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSemantic proximity Read

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.Semantic proximity Read

Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.Semantic proximity Read

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Semantic proximity Read

The combination of single-cell and bulk RNA sequencing analysis decodes the melanoma tumor microenvironment and identifies novel T cell-associated signature genesSemantic proximity Read

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.Semantic proximity Read

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.Semantic proximity Read

A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.Semantic proximity Read

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.Semantic proximity Read

Tumor immunogenomic signatures improve a prognostic model of melanoma survival.Semantic proximity Read

Transcriptional analysis of immune modulatory genes in melanoma treated with PD-1 blockadeSemantic proximity Read